Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: ALTERN8 who wrote (10442)	2/4/2003 9:14:23 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

ARIA news>ARIAD Licenses Its ARGENT Cell-Signaling Regulation Technology to GPC Biotech Tuesday February 4, 7:31 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2003--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced a non-exclusive license agreement with GPC Biotech AG (Frankfurt Stock Exchange: GPC) that gives GPC Biotech the right to use ARIAD's proprietary ARGENT(TM) cell-signaling regulation technology in GPC's proprietary LeadCode(TM) drug discovery and Reverse Genomics(TM) platform. ARIAD will receive guaranteed license fees of $2 million, including $1 million upon signing. GPC Biotech will use ARIAD's technology both in its internal drug discovery efforts and in partnerships with pharmaceutical and biotechnology companies.